For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Efficacy and Safety of Rhus verniciflua Stokes Extracts in Patients with Previously Treated Advanced Non-Small Cell Lung CancerCheon S.H.a · Kim K.S.b · Kim S.c · Jung H.S.b · Choi W.C.b · Eo W.K.a
a Department of Internal Medicine, M×µ Integrative Cancer Center, East West Neo Medical Center, Kyung Hee University College of Medicine, b Department of Oriental Oncology, M×µ Integrative Cancer Center, East West Neo Medical Center, Kyung Hee University College of Oriental Medicine, c Graduate School of East West Medical Science, Kyung Hee University, Seoul, Korea
Background: Systemic treatments for advanced non-small cell lung cancer (NSCLC) have modest survival benefits but high toxicity. Rhus verniciflua Stokes (RVS), the lacquer tree, is an ancient traditional medicine being used for the treatment of cancer. We investigated the efficacy and safety of allergen-removed RVS extract (aRVS) for the prolongation of survival in NSCLC after the failure of first-line or secondline chemotherapy. Patients and Methods: We reviewed the medical records of 40 patients who were treated with aRVS for previously treated, advanced NSCLC at the M×µ Integrative Cancer Center, Korea, between June 2006 and June 2009. The primary objective of this study was to assess overall survival. Secondary objectives included assessments of disease control rates, progression-free survival, and the safety of aRVS treatment. Results: The median survival time was 8.4 months with a 1-year survival of 40%. The disease control rate was 63.6%, and the median progression-free survival interval was 3.9 months. Patients who had better performance status and adenocarcinoma experienced more favorable outcomes in terms of overall survival. in aRVS treatment were negligible, with the most common drug-related adverse events being mild epigastric pain and itching skin. Hematologic toxicity was absent. Conclusions: Survival data and favorable levels of tolerability suggest the potential of aRVS treatment in previously treated patients with advanced NSCLC. Treatment with aRVS might be a viable alternative in patients for whom chemotherapy is not feasible, or who refuse chemotherapy.
© 2011 S. Karger AG, Basel